Inhibikase Share Price

Inhibikase Share Price

NASDAQ: IKT | Micro Cap | Healthcare
$1.30
+0.00 (0.00%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Inhibikase Stock Performance

Open
$1.30
Prev. Close
$1.30
Circuit Range
N/A
Day Range
$1.29 - $1.36
Year Range
$1.28 - $2.61
Volume
1,32,098
Average Traded
$1.32

Inhibikase Share Price Today

As of 21 November 2026, Inhibikase Therapeutics, Inc.'s share price is $1.30. The stock opened at $1.30, compared to its previous close of $1.30. During today's trading session, Inhibikase Therapeutics, Inc.'s share price traded between $1.29 and $1.36, with an average price of $1.33. Over the past 52 weeks, the stock has recorded a high of $2.61 and a low of $1.28. In terms of performance, Inhibikase Therapeutics, Inc.'s share price has declined by 25.00% over the last six months and is down 15.53% on a year-on-year basis.

Inhibikase Share Price Chart

Line chart of the Inhibikase price trend over the selected period. The price rose overall, ranging from 1.29 to 1.36, ending at 1.30.
$1.29$1.36
L
Show Current Price
H

Inhibikase Stock Fundamentals & Key Indicators

Market Cap
$128.29M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.49
Revenue (TTM)
$0.00
Return On Equity (TTM)
-36.64%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-60.80%

Inhibikase Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$12.73-$16.38-$19.59-$20.47
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-28.67%-19.60%-4.49%

Inhibikase Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.12$0.26$0.00$0.00
Net Profit-$18.05-$19.03-$27.52-$48.26
Net Profit Margin-15041.67%-7319.23%N/AN/A
Income ChangeN/A-5.43%-44.61%-75.36%

Inhibikase Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets1.10.150.30.57
Current Assets180.1198.4514.2124.37
Total Assets181.298.614.5124.94
Non Current Liabilities0.00.00.090.21
Current Liabilities8.33.733.443.7
Total Liabilities8.33.733.533.9
Shareholders' Equity172.994.8710.9821.04

Inhibikase Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-27.79-19.15-18.09-17.35
Investing2.05-37.011.66-16.01
Financing108.46103.488.41-0.2

Corporate Actions

Split
Ex-date: 30 Jun 2023

About Inhibikase

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Inhibikase Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$1.56
$1.31
-15.48%
Oct 2026
$2.05
$1.55
-24.76%
Sep 2026
$2.35
$2.06
-16.94%
Aug 2026
$2.23
$2.48
+13.76%
Jul 2026
$2.04
$2.18
+7.44%
Jun 2026
$1.77
$2.03
+16.61%
May 2026
$1.87
$1.74
-7.94%
Apr 2026
$1.71
$1.89
+13.17%
Mar 2026
$1.94
$1.67
-18.54%
Feb 2026
$1.57
$2.05
+36.67%
Jan 2026
$2.04
$1.50
-27.18%
Dec 2025
$1.53
$2.06
+33.33%

Inhibikase Share Price FAQs